K-Line Chart, actual market data is subject to the trading page.
Key Data
Prev. Open
$1.17
Prev. Close
$1.41
Prev. Day's Range
$1.16 - $1.53
52W Range
$0.93 - $7.44
Trading Volume
16.228M
MC
$393.971M
P/E Ratio
--
EPS
$-1.11
Company Overview
NASDAQ
Zura Bio Limited (Ticker: ZURA) is a biotechnology company focused on creating innovative therapies for autoimmune disorders and rare diseases. The company boasts a robust pipeline of drug candidates, supported by advanced research methodologies and comprehensive clinical trials aimed at demonstrating efficacy and safety. Backed by a seasoned management team and strategic partnerships, Zura Bio is strategically positioned to leverage opportunities in the biopharmaceutical sector, presenting a compelling investment opportunity for institutional investors interested in cutting-edge therapeutic advancements.
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
Headquarters1489 W. WARM SPRINGS ROAD, HENDERSON, NV, UNITED STATES, 89014
Zura Bio, Inc. (ZURA) is a clinical-stage biotechnology company specializing in developing therapies for immune-related and inflammatory diseases. The company aims to address unmet medical needs by targeting key pathways implicated in immune dysfunction. Its innovative pipeline reflects a strong focus on driving advancements in precision medicine within its field.
Zura Bio, Inc. operates in the healthcare sector, specifically within the biotechnology industry. This industry is known for companies engaged in researching and developing pharmaceutical and biological treatments, often targeting complex diseases and conditions.
ZURA offers investment potential through its focus on developing targeted treatments for immune-related diseases, a growing market driven by advances in biotechnology. Its innovative pipeline could address unmet medical needs, creating opportunities for market adoption. However, risks include clinical trial outcomes, regulatory hurdles, and competition in the biotechnology space.
ZURA’s financial performance could be influenced by the success or failure of its clinical trials, regulatory approvals, and strategic partnerships. Additionally, competitive dynamics within the biotechnology industry and the funding required to support ongoing research and development are critical factors for the company’s performance.
Zura Bio faces competition from other biotechnology companies that are also focused on immune-related and inflammatory diseases. Prominent competitors include both large, established pharmaceutical companies and smaller biotech firms, all striving to develop innovative therapies in this growing market space.
Zura Bio, Inc. does not currently pay dividends, as is common for clinical-stage biotechnology companies. Instead, it reinvests resources into research and development to advance its pipeline of therapies for immune-related and inflammatory diseases.
Key risks include the inherent uncertainty of clinical trial outcomes, the need to secure regulatory approvals, and possible delays in drug development. Other factors include high research and development costs, reliance on external funding, and competition from other biotech and pharmaceutical companies.
Zura Bio plans to generate revenue by commercializing its therapies upon successful clinical trials and regulatory approval. Additional revenue opportunities may include securing partnerships or licensing agreements with larger pharmaceutical companies, particularly if its therapies demonstrate strong market potential.
Risk Warning
1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
3.The information contained on this page is for reference only and does not constitute any investment advice.
Transfer
